FDA selects Dexcom as first TEMPO digital health pilot participant, ushering in a new paradigm of AI-driven chronic disease management

FDA Selects Dexcom as First TEMPO Digital Health Pilot Participant, Ushering in a New Paradigm of AI-Driven Chronic Disease Management

The U.S. Food and Drug Administration (FDA) officially announced on July 22 that it has selected Dexcom, a leader in continuous glucose monitoring (CGM), as the first participant in its "Technology Enabled Medical Precision Outcomes" (TEMPO) digital health pilot. Launched in late 2025, the pilot aims to explore the real-world performance of digital health devices and unlock Medicare reimbursement pathways. Dexcom plans to integrate its CGM sensors with artificial intelligence algorithms to build early screening and intervention programs for prediabetes and type 2 diabetes. This milestone marks a profound transformation in the U.S. medical technology regulatory and payment landscape, and provides a benchmark case for the convergence of Digital Health, AI Healthcare, and Medical Devices.

Industry Background: Dual Bottlenecks in Digital Health Regulation and Reimbursement

For a long time, digital health devices have faced two major challenges: lengthy regulatory approval cycles and unclear reimbursement pathways. The FDA’s traditional premarket review processes (e.g., 510(k) or PMA) often prove too rigid for digital health products that require frequent software updates. Meanwhile, CMS’s limited coverage of remote monitoring and AI-assisted diagnostics has made commercialization difficult for companies. In 2025, the FDA and CMS jointly launched the TEMPO pilot to break this deadlock: participating companies can collect real-world data while being exempt from certain premarket requirements, and receive Medicare reimbursement through CMS’s innovative payment models. Dexcom’s selection as the first participant signals that regulators are open to digital health solutions with strong evidence and high clinical value.

Key Progress: Dexcom’s AI Health Plan

In its announcement, Dexcom stated that during the pilot, it will integrate its prescription G7 CGM, over-the-counter Stelo device, and data from nutrition, exercise, sleep, stress, and other dimensions, using AI algorithms to provide users with a comprehensive view of metabolic health. The core objective of the program is to improve blood glucose control, helping people with prediabetes delay or prevent progression to type 2 diabetes through early warnings and personalized recommendations. Notably, Dexcom released evidence in June demonstrating the effectiveness of its sensors in type 2 diabetes patients. The pilot will shift evidence generation from clinical trials to real-world settings while securing CMS coverage.

The FDA noted that the TEMPO pilot plans to accept up to 10 manufacturers in each of CMS’s four priority disease areas (hypertension, diabetes, heart disease, chronic kidney disease, musculoskeletal pain, anxiety, and depression). Letters of intent are still being accepted with no deadline. This means Dexcom’s selection may be just the beginning, with more companies expected to join in the future.

Market Impact: Who Will Benefit?

Dexcom’s direct benefit is clear: through the pilot, its CGM devices’ market penetration will expand from type 1 diabetes, which already has Medicare coverage, to the vast population of prediabetes and type 2 diabetes.Dexcom's direct benefits are obvious: through the pilot, its CGM devices will expand market penetration from Type 1 diabetes (already covered by Medicare) to the vast pre-diabetic and Type 2 diabetes populations. According to CDC data, over 96 million adults are pre-diabetic, but most are not monitored. If Dexcom's AI health program gains clinical approval, it will open up a multi-billion dollar new market.

• From an industry perspective, this model benefits the following types of companies:
• Digital health companies with strong evidence-generation capabilities: such as continuous monitoring and remote patient monitoring platforms, as long as they can accumulate effective data in the real world, they can obtain regulatory clearance and payment access faster.
• AI medical imaging and diagnostic software developers: similar to the logic of CGM, imaging AI-assisted diagnostic systems can validate clinical utility through pilots, shortening the approval cycle.
• Medical device giants: such as Abbott (with its Libre series of CGM), Medtronic (diabetes management solutions), etc., are likely to follow Dexcom in applying to participate.

Hospitals and physician groups will also benefit: by accessing FDA-recognized and CMS-paid digital health solutions, they can improve chronic disease management efficiency and reduce readmission rates.

Challenges and Risks

Alongside opportunities, challenges are equally significant. First, the quality of real-world data may vary; how to ensure the data collected by devices is accurate, complete, and compliant with research standards is an issue that FDA and CMS need to address together. Second, the fairness and privacy protection of AI algorithms in real-world settings—Dexcom's algorithms need to be validated for performance across different racial and socioeconomic backgrounds to avoid exacerbating health inequities. Third, FDA's exemption from premarket review does not mean relaxed regulation; companies still bear ongoing monitoring and adverse event reporting obligations. If problems arise, the credibility of the entire pilot could be impacted. Additionally, whether CMS's payment model (lasting 10 years) is sustainable and the rates are reasonable also affects companies' long-term return on investment.

Future Outlook: Digital Health Enters an Era Driven by Both Regulation and Payment

In the next 3-5 years, the TEMPO pilot may become a watershed for the U.S. digital health industry. If significant results are achieved, the FDA may expand the scope of exemptions, promoting more Software as a Medical Device (SaMD) products to adopt the path of "real-world evidence + conditional approval." Meanwhile, CMS is expected to incorporate remote monitoring and AI decision support into core chronic disease management payment packages, forming a value-based model similar to "pay for performance." It is estimated that by 2030, the U.S. digital health market will grow from approximately $200 billion in 2025 to over $400 billion, with sub-sectors such as CGM, AI diagnostics, and remote therapy leading the growth.

Conclusion: From Approval to Payment, the Entire Chain Is Unblocked

Dexcom's selection for the TEMPO pilot is not just good news for one company; it reflects a policy shift in coordination between the FDA and CMS on digital health.## Conclusion: From Approval to Payment, the Entire Chain is Connected

Dexcom's selection for the TEMPO pilot is not only good news for the company, but also reflects the synergistic shift in digital health policy between the FDA and CMS. Regulators are no longer solely focused on device safety and efficacy; they are actively integrating the payment side into the innovation chain, forming a closed loop of "evidence generation—regulatory approval—Medicare coverage." This trend will accelerate the deployment of Healthcare Innovation, especially in chronic disease management, a major area of medical expenditure. The capital market's response also confirms market confidence: after the announcement, Dexcom's stock rose about 4% in after-hours trading, while the pace of follow-up by competitors such as Abbott and Medtronic is worth watching. It is foreseeable that future competition in medical technology will increasingly revolve around "the ability to obtain both regulatory approval and payment access."